Antigens That Trigger Type 1 Diabetes Identified

Antigens that may trigger type 1 diabetes have been identified by scientists from the University of Colorado. Type-1 diabetes is an auto-immune form of diabetes, in which insulin-producing beta cells in the pancreas are destroyed by body's own immune cells.//

"Our lab studies the type of T cell known as a CD4 T cell," said Kathryn Haskins from the University of Colorado School of Medicine in the US.

Subset of Patients With Strong Response to Therapy Identified By ITN Type 1 Diabetes Study
Patients with type 1 diabetes treated with the monoclonal antibody teplizumab exhibit greater preservation of C-peptide, compared to controls, according to a new clinical trial.

‘About 15,000 children are diagnosed with diabetes each year. Approximately 15 percent of Americans with type 1 diabetes are children. ’

Tweet it Now

"We have focused on autoreactive CD4 T cells using a mouse model of autoimmune diabetes. We have been especially interested in identifying the antigens that activate these T cells," Haskins added in the paper published in journal Science.

Normally, a CD4 T cell is supposed to respond to "foreign" antigens. But in autoimmune disease the T cells respond to antigens that are generated in the body. Such proteins and peptides are called autoantigens.

When an autoreactive T cell sees its antigen, it becomes activated and can initiate disease. By identifying those antigens, scientists may be able to use that information to detect autoreactive T cells early in disease, or better yet, in at-risk individuals.

A Key Factor in Mortality in Type 1 Diabetes Is Social Deprivation: Study
An independent risk factor for mortality in people with type 1 diabetes are the levels of social deprivation, as well as how well a patient controls their blood sugar.

If they are able to use the antigens to turn off destructive T cells, they may be able to prevent the disease, the study finds.

Researchers conducted experiments to analyze the fractions of beta cells that contain antigen for autoreactive CD4 T cells in order to identify autoantigens in type 1 diabetes.

Research Sheds Light on Targeting Memory T-Cells in Type 1 Diabetes
Some promising results from the T1DAL study are published in the latest issue of The Lancet Diabetes & Endocrinology.

They discovered a new class of antigens that consist of insulin fragments fused to peptides of other proteins present in beta cells. That fusion leads to generation of hybrid insulin peptides that are not encoded in an individual's genome.

If peptides in the body are modified from their original form, they essentially become "foreign" to the immune system and this may explain why they become targets for the autoreactive T cells.

Experimental Drug Found to be Effective in Blocking Type 1 Diabetes in Clinical Trials
A phase 2 clinical trial has reported positive results in half of the patients who took part in the trial.

The discovery of hybrid peptides as targets of the immune system provides a plausible explanation of how the immune system is tricked into destroying the body's own beta cells. The discovery may also lead to a better understanding of other autoimmune diseases.

Source-IANS